dromlakhani Pregnancy-Specific PPGL Medical Management
STEP 1 — Gather Information
Confirm pregnancy status and gestational age; obtain biochemical PPGL markers (24‑hour urinary fractionated metanephrines or plasma‑free fractionated metanephrines); perform obstetric‑safe imaging (ultrasound first, MRI if needed) to localize tumor; assess maternal blood pressure, heart rate, symptoms, and fetal well‑being.
Action: Proceed to step 2 if PPGL is biochemically confirmed and imaging shows a lesion.
STEP 2 — Rule In / Rule Out
Rule out pregnancy‑related hypertension (preeclampsia, gestational hypertension) by checking for proteinuria, liver enzymes, platelets, and absence of PPGL biochemical excess; if catecholamine metabolites are ≥3× upper limit, rule in PPGL.
Action: If PPGL ruled in, move to step 3; otherwise manage as routine hypertensive disorder of pregnancy.
STEP 3 — Classify or Stratify
Stratify by gestational age and hypertension severity: <24 weeks → consider tumor resection if feasible; ≥24 weeks → prioritize medical control until delivery; classify BP as mild (<150/100 mmHg) or severe (≥150/100 mmHg) to guide agent intensity.
Action: Select medical management pathway based on stratum.
STEP 4 — Decide
Initiate a selective α‑blocker (e.g., prazosin 0.5–1 mg at bedtime, titrate to effect); if BP remains uncontrolled, add a calcium antagonist (nifedipine ER 30–60 mg daily or amlodipine 5–10 mg daily); avoid metyrosine, ARBs, ACE‑Is, and direct renin inhibitors; use β‑blockers only for refractory tachycardia after adequate α‑blockade; consider magnesium sulfate for preeclampsia‑range hypertension; plan surgical resection in the second trimester (up to 24 weeks) only if tumor is resectable and maternal/fetal status permits.
Action: Implement chosen pharmacologic regimen and arrange multidisciplinary review for possible surgery.
Clinical Guardrails / Mimics / Pitfalls
Do not start β‑blockers before α‑blockade (risk of hypertensive crisis); avoid metyrosine due to unknown fetal safety; ARBs, ACE‑Is, and direct renin inhibitors are contraindicated (fetotoxicity); limit CT and 123I‑MIBG scintigraphy unless maternal benefit clearly outweighs fetal radiation risk; monitor for orthostatic hypotension and fetal growth restriction; magnesium sulfate is reserved for preeclampsia, not routine PPGL hypertension.
Concrete Clinical Example
A 32‑year‑old G2P1 at 18 weeks gestation presents with episodic headaches, palpitations, and BP 168/102 mmHg. Urinary fractionated metanephrines are 5× upper limit; MRI shows a 2.8 cm left adrenal lesion. No proteinuria. Start prazosin 0.5 mg nightly; after 3 days BP 148/94 mmHg, increase to 1 mg nightly; BP 138/88 mmHg achieved. Continue α‑blocker alone, plan laparoscopic adrenalectomy at 22 weeks after anesthesia and obstetric clearance.
Source: Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, doi:10.1507/endocrj.EJ25-0165